Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease.

Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Nitric Oxide (Impact Factor: 3.27). 04/2011; 25(2):81-8. DOI: 10.1016/j.niox.2011.04.004
Source: PubMed

ABSTRACT Nitric oxide, generated by the nitric oxide synthase (NOS) enzymes, plays pivotal roles in cardiovascular homeostasis and in the pathogenesis of cardiovascular disease. The NOS cofactor, tetrahydrobiopterin (BH4), is an important regulator of NOS function, since BH4 is required to maintain enzymatic coupling of L-arginine oxidation, to produce NO. Loss or oxidation of BH4 to 7,8-dihydrobiopterin (BH2) is associated with NOS uncoupling, resulting in the production of superoxide rather than NO. In addition to key roles in folate metabolism, dihydrofolate reductase (DHFR) can 'recycle' BH2, and thus regenerate BH4. It is therefore likely that net BH4 cellular bioavailability reflects the balance between de novo BH4 synthesis, loss of BH4 by oxidation to BH2, and the regeneration of BH4 by DHFR. Recent studies have implicated BH4 recycling in the direct regulation of eNOS uncoupling, showing that inhibition of BH4 recycling using DHFR-specific siRNA and methotrexate treatment leads to eNOS uncoupling in endothelial cells and the hph-1 mouse model of BH4 deficiency, even in the absence of oxidative stress. These studies indicate that not only BH4 level, but the recycling pathways regulating BH4 bioavailability represent potential therapeutic targets and will be discussed in this review.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperglycemia worsens outcome in stroke patients and in a variety of stroke models, most prominently following prolonged ischemia and reperfusion. Vascular dysfunction has been associated with this worsened outcome, manifested by reduced reperfusion cerebral blood flow (CBF), as well as increased hemorrhagic transformation, edema, and mortality. The phenomenon of “uncoupling” of endothelial nitric oxide synthase (eNOS) has been associated with hyperglycemia in the periphery and results in a dysfunctional eNOS-generating superoxide radical ( $ {\text{O}}_2^{ - } $ ) in lieu of nitric oxide (NO). A net result of NOS uncoupling is reduction in blood flow and generation of a pro-thrombotic, inflammatory vascular phenotype that could explain many of the features of hyperglycemic stroke. Because the sources of increased $ {\text{O}}_2^{ - } $ and mechanisms of reduced NO are difficult to identify under in vivo pathological conditions, we have termed the presence of perivascular excess of $ {\text{O}}_2^{ - } $ expression relative to NO as “functional uncoupling.” We hypothesized that hyperglycemia would induce a state of functional uncoupling in the cerebral microvasculature that would be exacerbated by transient focal ischemia. We examined the relative expression of systemically injected radical sensitive dyes in cerebral microvessel profiles in the basal and 24 h post-stroke brain in a rat model of middle cerebral artery occlusion and recanalization (MCAO/R) in controls and after hyperglycemia. We focused on the peri-infarct region because of its importance in penumbra extension and edema. Differential expression of fluorescent dyes sensitive to $ {\text{O}}_2^{ - } $ and NO in microvessel profiles were assessed in the peri-infarct region. Hyperglycemia was induced by streptozotocin 48 h prior to MCAO/R. We found that hyperglycemia resulted in an increase in $ {\text{O}}_2^{ - } $ relative to NO, a pattern consistent with functional uncoupling. This ratio was accentuated 24 h after MCA/O in both groups. Hyperglycemic rats showed a synergistic increase in the $ {\text{O}}_2^{ - } $ /NO ratio as well as reduced acute reperfusion CBF, increased infarct size, and enhanced expression of nitrotyrosine. While effects of hyperglycemia on oxidative radicals is well known, we showed for the first time that hyperglycemia synergistically worsened functional uncoupling in the peri-infarct microvasculature and that it persisted for the 24-h duration of the experiment. Persistent generation of microvascular $ {\text{O}}_2^{ - } $ and reduction in NO expression suggest potential late therapeutic targets to restore microvessel function and improve vascular outcomes in hyperglycemic stroke.
    Translational Stroke Research. 3(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO) signaling plays a major role in modulating vascular tone and remodeling in the pulmonary circulation, but its role in the pathogenesis of pulmonary vascular diseases is still not completely understood. Numerous abnormalities of NO synthesis and signaling have been identified in animal models of pulmonary vascular disease and in humans with pulmonary hypertension. Many of these abnormalities have become targets of new therapies for the treatment of pulmonary hypertension. However, it is unclear to what extent alterations in NO signaling contribute to pulmonary hypertensive responses or merely reflect abnormalities induced by the underlying disease. This perspective examines the current understanding of altered NO signaling in pulmonary hypertensive diseases and discusses how these alterations may contribute to the pathogenesis of pulmonary hypertension. The efficacy and limitations of presently available therapies for pulmonary hypertension that target NO signaling are reviewed along with an update on investigational therapies that also utilize this pathway to reverse pulmonary hypertensive changes.
    American Journal of Respiratory and Critical Care Medicine 07/2013; · 11.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endothelial dysfunction contributes to the initiation and development of hypertension. We previously found that simvastatin moderately decreases blood pressure in 2-kidney-2-clip (2k2c) renal hypertension, but the precise mechanisms are still unclear. The present study was designed to examine the protective actions of simvastatin in 2k2c-evoked endothelial dysfunction and also delineate the underlying mechanisms. Here we show that 2k2c-induced elevation in plasma angiotensin II impaired acetylcholine-induced endothelium-dependent vascular relaxation, suppressed endothelial NO synthase (eNOS) activity and reduced nitric oxide (NO) production. Additionally, the levels of tetrahydrobiopterin (BH4), an essential cofactor of eNOS, as well as the activity of GTP cyclohydrolase I (GTPCH I), the rate-limiting enzyme for BH4 synthesis, were markedly reduced. Administration of simvastatin significantly improved acetylcholine-induced endothelium-dependent carotid arteries relaxation at 9 weeks in reno-hypertensive rats. Notably, GTPCH I activity, BH4 production, p-eNOS expression and NO levels in the vascular endothelium were elevated as a result of simvastatin administration. In cultured rat arterial endothelial cells, simvastatin restored BH4, GTPCH I activity and NO release impaired by angiotensin II, and pretreatment with mevalonate (MVA) or geranylgeranyl pyrophosphate (GGPP) abolished the beneficial effects exerted by simvastatin. Moreover, RhoA inhibitor C3 exoenzyme, Rho kinase inhibitor Y-27632 and dominant negative mutant of RhoA prevented BH4 and NO loss due to Ang II treatment. Taken together, normalization of BH4-eNOS-NO pathway at least in part accounts for the beneficial actions of simvastatin on vascular endothelium during 2k2c hypertension, and RhoA-Rho kinase pathway is involved in regulation of BH4 production.
    Cardiovascular Drugs and Therapy 11/2011; 26(1):31-40. · 2.67 Impact Factor